Early Initiation of Evolocumab Treatment in Chinese Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

医学 Evolocumab公司 急性冠脉综合征 内科学 传统PCI 危险系数 经皮冠状动脉介入治疗 心肌梗塞 心脏病学 他汀类 不稳定型心绞痛 中止 回顾性队列研究 载脂蛋白B 胆固醇 置信区间 载脂蛋白A1
作者
Yahao Zhang,Yanghui Zhang,Bin Zhang,Zheng Chen,Yongjie Wei,Penglei Chen,Chao Chang,Guizhi Liu,Kui Chen,Jiandong Ding,Zhengming Jiang
出处
期刊:Clinical Therapeutics [Elsevier BV]
卷期号:44 (6): 901-912 被引量:8
标识
DOI:10.1016/j.clinthera.2022.04.010
摘要

Evolocumab has been shown to improve cardiovascular outcomes in patients with stable atherosclerotic disease. Whether this benefit persists in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) remains undetermined. This study aimed to evaluate the efficacy and safety of the early initiation of evolocumab in Chinese patients with ACS undergoing PCI.This retrospective cohort study involved 1564 consecutive patients who had been hospitalized with ACS and underwent PCI, and who had elevated LDL-C levels (≥1.8 mmol/L after receiving high-intensity statin therapy for ≥4 weeks; ≥2.3 mmol/L after receiving low- or moderate-intensity statin; or ≥3.2 mmol/L without statin therapy). Patients who received evolocumab (initiated in-hospital and after 18 months) were included in the evolocumab group (n = 414), and all other patients were included in the control group (n = 1150). The primary outcome at 18 months was a composite of ischemic stroke, cardiovascular death, myocardial infarction, hospitalization for unstable angina, or coronary revascularization. The evolocumab treatment effect on the primary outcome was assessed in all prespecified subgroups.At 18 months, evolocumab combined with statins reduced LDL-C levels from baseline levels by 42.48% compared with statins alone. After multivariable adjustment, evolocumab combined with statins significantly reduced the primary outcome (8.2% vs 12.4%; adjusted hazard ratio, 0.65; 95% CI, 0.45-0.95; P = 0.025). In addition, evolocumab consistently reduced the primary outcome across the major subgroups. For the safety outcomes, no significant differences between the groups were observed in any adverse events.Among Chinese patients who underwent PCI for ACS, the early initiation of evolocumab combined with statin treatment effectively reduced LDL-C levels and lowered the incidence of recurrent ischemic cardiovascular events, with satisfactory tolerability and safety. Chinese Clinical Trial Registry identifier: ChiCTR2100049364.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
rhx完成签到,获得积分10
1秒前
奋斗瑶发布了新的文献求助30
1秒前
wisdom完成签到,获得积分10
2秒前
180090094745完成签到,获得积分10
2秒前
活力的寻云完成签到 ,获得积分10
2秒前
2秒前
agui发布了新的文献求助10
3秒前
3秒前
害羞大碗发布了新的文献求助10
5秒前
5秒前
liu发布了新的文献求助10
5秒前
6秒前
牢大完成签到 ,获得积分10
6秒前
6秒前
6秒前
7秒前
PAD发布了新的文献求助30
7秒前
苹果友桃完成签到,获得积分10
9秒前
江南第八完成签到,获得积分10
9秒前
vuuu发布了新的文献求助10
10秒前
许雨青发布了新的文献求助10
10秒前
11秒前
斯文败类应助金鑫水淼采纳,获得10
12秒前
青未发布了新的文献求助10
13秒前
高高不二发布了新的文献求助10
13秒前
害羞大碗完成签到,获得积分10
14秒前
852应助开朗的早晨采纳,获得10
14秒前
呆萌的如天完成签到,获得积分10
15秒前
在水一方应助稳重向南采纳,获得10
15秒前
16秒前
16秒前
17秒前
酱喵完成签到 ,获得积分10
17秒前
1213发布了新的文献求助30
17秒前
科研通AI2S应助KK采纳,获得10
17秒前
wuyan发布了新的文献求助10
17秒前
高高不二完成签到,获得积分10
19秒前
20秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 360
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3971395
求助须知:如何正确求助?哪些是违规求助? 3516110
关于积分的说明 11180848
捐赠科研通 3251238
什么是DOI,文献DOI怎么找? 1795760
邀请新用户注册赠送积分活动 876012
科研通“疑难数据库(出版商)”最低求助积分说明 805228